Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
2 reports, 2 independent
Updated Sep 22
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Cantor Fitzgerald reaffirmed overweight rating for Aligos Therapeutics.1 source
Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma.1 source
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
aTyr Pharma
company in San Diego, United States
Nothing else this week.
-
Aligos Therapeutics, Inc.
Nothing else this week.
Related events
- Cantor Fitzgerald reiterated an Overweight rating on Amazon stock.
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Cantor Fitzgerald reiterated an overweight rating on CleanSpark shares.
- Cantor Fitzgerald hosted a healthcare conference on September 8, 2026.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- Insider MonkeyATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the top multibagger penny stocks to buy, according to analysts. On August 4,